APO Research
Talk to an analyst

APO RESEARCH · REPORT

RNA-based Biopharmaceuticals

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global RNA-based Biopharmaceuticals Market Outlook and Growth Opportunities 2026

21 December 2025206 pages

Choose your research edition.

Industry ResearchRNA-based Biopharmaceuticals Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal RNA-based Biopharmaceuticals Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal RNA-based Biopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal RNA-based Biopharmaceuticals Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal RNA-based Biopharmaceuticals Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global RNA-based Biopharmaceuticals market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for RNA-based Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for RNA-based Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for RNA-based Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the RNA-based Biopharmaceuticals market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the RNA-based Biopharmaceuticals market include Roche, Pfizer, Tekmira, Silenseed, Silence Therapeutics, Senesco, Sanofi-Aventis, RXi and Quark, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global RNA-based Biopharmaceuticals market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of RNA-based Biopharmaceuticals and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents RNA-based Biopharmaceuticals sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the RNA-based Biopharmaceuticals market size, projected growth trends, production technologies, key applications, and end-use industries.

RNA-based Biopharmaceuticals Segment by Company

Roche

Pfizer

Tekmira

Silenseed

Silence Therapeutics

Senesco

Sanofi-Aventis

RXi

Quark

Gradalis

Dicerna

Calimmune Inc

Benitec Biopharma

Arrowhead Pharmaceuticals

Alnylam Pharmaceuticals

Abbott Laboratories

RNA-based Biopharmaceuticals Segment by Type

Therapeutics

Vaccines

RNA-based Biopharmaceuticals Segment by Application

Cancer

Tuberculosis

Diabetes

Cardiovascular Diseases

Others

RNA-based Biopharmaceuticals Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global RNA-based Biopharmaceuticals status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions RNA-based Biopharmaceuticals market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify RNA-based Biopharmaceuticals significant trends, drivers, influence factors in global and regions.

6. To analyze RNA-based Biopharmaceuticals competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA-based Biopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of RNA-based Biopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA-based Biopharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the RNA-based Biopharmaceuticals market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global RNA-based Biopharmaceuticals industry.

Chapter 3: Detailed analysis of RNA-based Biopharmaceuticals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of RNA-based Biopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of RNA-based Biopharmaceuticals in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. RNA-based Biopharmaceuticals Industry Trends Table 2. RNA-based Biopharmaceuticals Industry Drivers Table 3. RNA-based Biopharmaceuticals Industry Opportunities and Challenges Table 4. RNA-based Biopharmaceuticals Industry Restraints Table 5. Global RNA-based Biopharmaceuticals Revenue by Company (US$ Million) & (2021-2026) Table 6. Global RNA-based Biopharmaceuticals Revenue Share by Company (2021-2026) Table 7. Global RNA-based Biopharmaceuticals Sales Volume by Company (k units) & (2021-2026) Table 8. Global RNA-based Biopharmaceuticals Sales Volume Share by Company (2021-2026) Table 9. Global RNA-based Biopharmaceuticals Average Price (US$/unit) of Company (2021-2026) Table 10. Global RNA-based Biopharmaceuticals Company Ranking, (2024-2026) & (USD Million) Table 11. Global RNA-based Biopharmaceuticals Key Company Manufacturing Base & Headquarters Table 12. Global RNA-based Biopharmaceuticals Company, Product Type & Application Table 13. Global RNA-based Biopharmaceuticals Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global RNA-based Biopharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Therapeutics Table 18. Significant Companies of Vaccines Table 19. Global RNA-based Biopharmaceuticals Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global RNA-based Biopharmaceuticals Sales Volume by Type (2021-2026) & (k units) Table 21. Global RNA-based Biopharmaceuticals Sales Volume by Type (2027-2032) & (k units) Table 22. Global RNA-based Biopharmaceuticals Sales Volume Share by Type (2021-2026) Table 23. Global RNA-based Biopharmaceuticals Sales Volume Share by Type (2027-2032) Table 24. Global RNA-based Biopharmaceuticals Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global RNA-based Biopharmaceuticals Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global RNA-based Biopharmaceuticals Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global RNA-based Biopharmaceuticals Sales Value Share by Type (2021-2026) Table 28. Global RNA-based Biopharmaceuticals Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Cancer Table 30. Significant Companies of Tuberculosis Table 31. Significant Companies of Diabetes Table 32. Significant Companies of Cardiovascular Diseases Table 33. Significant Companies of Others Table 34. Global RNA-based Biopharmaceuticals Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global RNA-based Biopharmaceuticals Sales Volume by Application (2021-2026) & (k units) Table 36. Global RNA-based Biopharmaceuticals Sales Volume by Application (2027-2032) & (k units) Table 37. Global RNA-based Biopharmaceuticals Sales Volume Share by Application (2021-2026) Table 38. Global RNA-based Biopharmaceuticals Sales Volume Share by Application (2027-2032) Table 39. Global RNA-based Biopharmaceuticals Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global RNA-based Biopharmaceuticals Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global RNA-based Biopharmaceuticals Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global RNA-based Biopharmaceuticals Sales Value Share by Application (2021-2026) Table 43. Global RNA-based Biopharmaceuticals Sales Value Share by Application (2027-2032) Table 44. Global RNA-based Biopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global RNA-based Biopharmaceuticals Sales by Region (2021-2026) & (k units) Table 46. Global RNA-based Biopharmaceuticals Sales Market Share by Region (2021-2026) Table 47. Global RNA-based Biopharmaceuticals Sales by Region (2027-2032) & (k units) Table 48. Global RNA-based Biopharmaceuticals Sales Market Share by Region (2027-2032) Table 49. Global RNA-based Biopharmaceuticals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global RNA-based Biopharmaceuticals Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global RNA-based Biopharmaceuticals Sales Value Share by Region (2021-2026) Table 52. Global RNA-based Biopharmaceuticals Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global RNA-based Biopharmaceuticals Sales Value Share by Region (2027-2032) Table 54. Global RNA-based Biopharmaceuticals Market Average Price (US$/unit) by Region (2021-2026) Table 55. Global RNA-based Biopharmaceuticals Market Average Price (US$/unit) by Region (2027-2032) Table 56. Global RNA-based Biopharmaceuticals Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global RNA-based Biopharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global RNA-based Biopharmaceuticals Sales by Country (2021-2026) & (k units) Table 59. Global RNA-based Biopharmaceuticals Sales Market Share by Country (2021-2026) Table 60. Global RNA-based Biopharmaceuticals Sales by Country (2027-2032) & (k units) Table 61. Global RNA-based Biopharmaceuticals Sales Market Share by Country (2027-2032) Table 62. Global RNA-based Biopharmaceuticals Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global RNA-based Biopharmaceuticals Sales Value Market Share by Country (2021-2026) Table 64. Global RNA-based Biopharmaceuticals Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global RNA-based Biopharmaceuticals Sales Value Market Share by Country (2027-2032) Table 66. Roche Company Information Table 67. Roche Business Overview Table 68. Roche RNA-based Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Roche RNA-based Biopharmaceuticals Product Portfolio Table 70. Roche Recent Development Table 71. Pfizer Company Information Table 72. Pfizer Business Overview Table 73. Pfizer RNA-based Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Pfizer RNA-based Biopharmaceuticals Product Portfolio Table 75. Pfizer Recent Development Table 76. Tekmira Company Information Table 77. Tekmira Business Overview Table 78. Tekmira RNA-based Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Tekmira RNA-based Biopharmaceuticals Product Portfolio Table 80. Tekmira Recent Development Table 81. Silenseed Company Information Table 82. Silenseed Business Overview Table 83. Silenseed RNA-based Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Silenseed RNA-based Biopharmaceuticals Product Portfolio Table 85. Silenseed Recent Development Table 86. Silence Therapeutics Company Information Table 87. Silence Therapeutics Business Overview Table 88. Silence Therapeutics RNA-based Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Silence Therapeutics RNA-based Biopharmaceuticals Product Portfolio Table 90. Silence Therapeutics Recent Development Table 91. Senesco Company Information Table 92. Senesco Business Overview Table 93. Senesco RNA-based Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Senesco RNA-based Biopharmaceuticals Product Portfolio Table 95. Senesco Recent Development Table 96. Sanofi-Aventis Company Information Table 97. Sanofi-Aventis Business Overview Table 98. Sanofi-Aventis RNA-based Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Sanofi-Aventis RNA-based Biopharmaceuticals Product Portfolio Table 100. Sanofi-Aventis Recent Development Table 101. RXi Company Information Table 102. RXi Business Overview Table 103. RXi RNA-based Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. RXi RNA-based Biopharmaceuticals Product Portfolio Table 105. RXi Recent Development Table 106. Quark Company Information Table 107. Quark Business Overview Table 108. Quark RNA-based Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Quark RNA-based Biopharmaceuticals Product Portfolio Table 110. Quark Recent Development Table 111. Gradalis Company Information Table 112. Gradalis Business Overview Table 113. Gradalis RNA-based Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Gradalis RNA-based Biopharmaceuticals Product Portfolio Table 115. Gradalis Recent Development Table 116. Dicerna Company Information Table 117. Dicerna Business Overview Table 118. Dicerna RNA-based Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Dicerna RNA-based Biopharmaceuticals Product Portfolio Table 120. Dicerna Recent Development Table 121. Calimmune Inc Company Information Table 122. Calimmune Inc Business Overview Table 123. Calimmune Inc RNA-based Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. Calimmune Inc RNA-based Biopharmaceuticals Product Portfolio Table 125. Calimmune Inc Recent Development Table 126. Benitec Biopharma Company Information Table 127. Benitec Biopharma Business Overview Table 128. Benitec Biopharma RNA-based Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. Benitec Biopharma RNA-based Biopharmaceuticals Product Portfolio Table 130. Benitec Biopharma Recent Development Table 131. Arrowhead Pharmaceuticals Company Information Table 132. Arrowhead Pharmaceuticals Business Overview Table 133. Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Product Portfolio Table 135. Arrowhead Pharmaceuticals Recent Development Table 136. Alnylam Pharmaceuticals Company Information Table 137. Alnylam Pharmaceuticals Business Overview Table 138. Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 139. Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Product Portfolio Table 140. Alnylam Pharmaceuticals Recent Development Table 141. Abbott Laboratories Company Information Table 142. Abbott Laboratories Business Overview Table 143. Abbott Laboratories RNA-based Biopharmaceuticals Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 144. Abbott Laboratories RNA-based Biopharmaceuticals Product Portfolio Table 145. Abbott Laboratories Recent Development Table 146. Key Raw Materials Table 147. Raw Materials Key Suppliers Table 148. RNA-based Biopharmaceuticals Distributors List Table 149. RNA-based Biopharmaceuticals Customers List Table 150. Research Programs/Design for This Report Table 151. Authors List of This Report Table 152. Secondary Sources Table 153. Primary Sources List of Figures Figure 1. RNA-based Biopharmaceuticals Product Image Figure 2. Global RNA-based Biopharmaceuticals Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global RNA-based Biopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 4. Global RNA-based Biopharmaceuticals Sales (2021-2032) & (k units) Figure 5. Global RNA-based Biopharmaceuticals Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global RNA-based Biopharmaceuticals Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Therapeutics Image Figure 10. Vaccines Image Figure 11. Global RNA-based Biopharmaceuticals Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global RNA-based Biopharmaceuticals Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global RNA-based Biopharmaceuticals Sales Volume Share by Type (2021-2032) Figure 14. Global RNA-based Biopharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global RNA-based Biopharmaceuticals Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global RNA-based Biopharmaceuticals Sales Value Share by Type (2021-2032) Figure 17. Cancer Image Figure 18. Tuberculosis Image Figure 19. Diabetes Image Figure 20. Cardiovascular Diseases Image Figure 21. Others Image Figure 22. Global RNA-based Biopharmaceuticals Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global RNA-based Biopharmaceuticals Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global RNA-based Biopharmaceuticals Sales Volume Share by Application (2021-2032) Figure 25. Global RNA-based Biopharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global RNA-based Biopharmaceuticals Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global RNA-based Biopharmaceuticals Sales Value Share by Application (2021-2032) Figure 28. Global RNA-based Biopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global RNA-based Biopharmaceuticals Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global RNA-based Biopharmaceuticals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global RNA-based Biopharmaceuticals Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America RNA-based Biopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 33. North America RNA-based Biopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe RNA-based Biopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 35. Europe RNA-based Biopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific RNA-based Biopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific RNA-based Biopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America RNA-based Biopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 39. South America RNA-based Biopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa RNA-based Biopharmaceuticals Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa RNA-based Biopharmaceuticals Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. RNA-based Biopharmaceuticals Value Chain Figure 127. Manufacturing Cost Structure Figure 128. RNA-based Biopharmaceuticals Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Therapeutics
  • Vaccines
Applications
  • Cancer
  • Tuberculosis
  • Diabetes
  • Cardiovascular Diseases
  • Others
Companies covered
  • Roche
  • Pfizer
  • Tekmira
  • Silenseed
  • Silence Therapeutics
  • Senesco
  • Sanofi-Aventis
  • RXi
  • Quark
  • Gradalis
  • Dicerna
  • Calimmune Inc
  • Benitec Biopharma
  • Arrowhead Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global RNA-based Biopharmaceuticals Sales Value (2021-2032)
  4. 1.2.2 Global RNA-based Biopharmaceuticals Sales Volume (2021-2032)
  5. 1.2.3 Global RNA-based Biopharmaceuticals Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 RNA-based Biopharmaceuticals Market Dynamics
  1. 2.1 RNA-based Biopharmaceuticals Industry Trends
  2. 2.2 RNA-based Biopharmaceuticals Industry Drivers
  3. 2.3 RNA-based Biopharmaceuticals Industry Opportunities and Challenges
  4. 2.4 RNA-based Biopharmaceuticals Industry Restraints
3 RNA-based Biopharmaceuticals Market by Company
  1. 3.1 Global RNA-based Biopharmaceuticals Company Revenue Ranking in 2025
  2. 3.2 Global RNA-based Biopharmaceuticals Revenue by Company (2021-2026)
  3. 3.3 Global RNA-based Biopharmaceuticals Sales Volume by Company (2021-2026)
  4. 3.4 Global RNA-based Biopharmaceuticals Average Price by Company (2021-2026)
  5. 3.5 Global RNA-based Biopharmaceuticals Company Ranking (2024-2026)
  6. 3.6 Global RNA-based Biopharmaceuticals Company Manufacturing Base and Headquarters
  7. 3.7 Global RNA-based Biopharmaceuticals Company Product Type and Application
  8. 3.8 Global RNA-based Biopharmaceuticals Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global RNA-based Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 RNA-based Biopharmaceuticals Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 RNA-based Biopharmaceuticals Market by Type
  1. 4.1 RNA-based Biopharmaceuticals Type Introduction
  2. 4.1.1 Therapeutics
  3. 4.1.2 Vaccines
  4. 4.2 Global RNA-based Biopharmaceuticals Sales Volume by Type
  5. 4.2.1 Global RNA-based Biopharmaceuticals Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global RNA-based Biopharmaceuticals Sales Volume by Type (2021-2032)
  7. 4.2.3 Global RNA-based Biopharmaceuticals Sales Volume Share by Type (2021-2032)
  8. 4.3 Global RNA-based Biopharmaceuticals Sales Value by Type
  9. 4.3.1 Global RNA-based Biopharmaceuticals Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global RNA-based Biopharmaceuticals Sales Value by Type (2021-2032)
  11. 4.3.3 Global RNA-based Biopharmaceuticals Sales Value Share by Type (2021-2032)
5 RNA-based Biopharmaceuticals Market by Application
  1. 5.1 RNA-based Biopharmaceuticals Application Introduction
  2. 5.1.1 Cancer
  3. 5.1.2 Tuberculosis
  4. 5.1.3 Diabetes
  5. 5.1.4 Cardiovascular Diseases
  6. 5.1.5 Others
  7. 5.2 Global RNA-based Biopharmaceuticals Sales Volume by Application
  8. 5.2.1 Global RNA-based Biopharmaceuticals Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global RNA-based Biopharmaceuticals Sales Volume by Application (2021-2032)
  10. 5.2.3 Global RNA-based Biopharmaceuticals Sales Volume Share by Application (2021-2032)
  11. 5.3 Global RNA-based Biopharmaceuticals Sales Value by Application
  12. 5.3.1 Global RNA-based Biopharmaceuticals Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global RNA-based Biopharmaceuticals Sales Value by Application (2021-2032)
  14. 5.3.3 Global RNA-based Biopharmaceuticals Sales Value Share by Application (2021-2032)
6 RNA-based Biopharmaceuticals Regional Sales and Value Analysis
  1. 6.1 Global RNA-based Biopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global RNA-based Biopharmaceuticals Sales by Region (2021-2032)
  3. 6.2.1 Global RNA-based Biopharmaceuticals Sales by Region: 2021-2026
  4. 6.2.2 Global RNA-based Biopharmaceuticals Sales by Region (2027-2032)
  5. 6.3 Global RNA-based Biopharmaceuticals Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global RNA-based Biopharmaceuticals Sales Value by Region (2021-2032)
  7. 6.4.1 Global RNA-based Biopharmaceuticals Sales Value by Region: 2021-2026
  8. 6.4.2 Global RNA-based Biopharmaceuticals Sales Value by Region (2027-2032)
  9. 6.5 Global RNA-based Biopharmaceuticals Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America RNA-based Biopharmaceuticals Sales Value (2021-2032)
  12. 6.6.2 North America RNA-based Biopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe RNA-based Biopharmaceuticals Sales Value (2021-2032)
  15. 6.7.2 Europe RNA-based Biopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific RNA-based Biopharmaceuticals Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific RNA-based Biopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America RNA-based Biopharmaceuticals Sales Value (2021-2032)
  21. 6.9.2 South America RNA-based Biopharmaceuticals Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa RNA-based Biopharmaceuticals Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa RNA-based Biopharmaceuticals Sales Value Share by Country, 2025 VS 2032
7 RNA-based Biopharmaceuticals Country-level Sales and Value Analysis
  1. 7.1 Global RNA-based Biopharmaceuticals Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global RNA-based Biopharmaceuticals Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global RNA-based Biopharmaceuticals Sales by Country (2021-2032)
  4. 7.3.1 Global RNA-based Biopharmaceuticals Sales by Country (2021-2026)
  5. 7.3.2 Global RNA-based Biopharmaceuticals Sales by Country (2027-2032)
  6. 7.4 Global RNA-based Biopharmaceuticals Sales Value by Country (2021-2032)
  7. 7.4.1 Global RNA-based Biopharmaceuticals Sales Value by Country (2021-2026)
  8. 7.4.2 Global RNA-based Biopharmaceuticals Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt RNA-based Biopharmaceuticals Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt RNA-based Biopharmaceuticals Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt RNA-based Biopharmaceuticals Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche
  2. 8.1.1 Roche Company Information
  3. 8.1.2 Roche Business Overview
  4. 8.1.3 Roche RNA-based Biopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Roche RNA-based Biopharmaceuticals Product Portfolio
  6. 8.1.5 Roche Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer RNA-based Biopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer RNA-based Biopharmaceuticals Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 Tekmira
  14. 8.3.1 Tekmira Company Information
  15. 8.3.2 Tekmira Business Overview
  16. 8.3.3 Tekmira RNA-based Biopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Tekmira RNA-based Biopharmaceuticals Product Portfolio
  18. 8.3.5 Tekmira Recent Developments
  19. 8.4 Silenseed
  20. 8.4.1 Silenseed Company Information
  21. 8.4.2 Silenseed Business Overview
  22. 8.4.3 Silenseed RNA-based Biopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Silenseed RNA-based Biopharmaceuticals Product Portfolio
  24. 8.4.5 Silenseed Recent Developments
  25. 8.5 Silence Therapeutics
  26. 8.5.1 Silence Therapeutics Company Information
  27. 8.5.2 Silence Therapeutics Business Overview
  28. 8.5.3 Silence Therapeutics RNA-based Biopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Silence Therapeutics RNA-based Biopharmaceuticals Product Portfolio
  30. 8.5.5 Silence Therapeutics Recent Developments
  31. 8.6 Senesco
  32. 8.6.1 Senesco Company Information
  33. 8.6.2 Senesco Business Overview
  34. 8.6.3 Senesco RNA-based Biopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Senesco RNA-based Biopharmaceuticals Product Portfolio
  36. 8.6.5 Senesco Recent Developments
  37. 8.7 Sanofi-Aventis
  38. 8.7.1 Sanofi-Aventis Company Information
  39. 8.7.2 Sanofi-Aventis Business Overview
  40. 8.7.3 Sanofi-Aventis RNA-based Biopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Sanofi-Aventis RNA-based Biopharmaceuticals Product Portfolio
  42. 8.7.5 Sanofi-Aventis Recent Developments
  43. 8.8 RXi
  44. 8.8.1 RXi Company Information
  45. 8.8.2 RXi Business Overview
  46. 8.8.3 RXi RNA-based Biopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 RXi RNA-based Biopharmaceuticals Product Portfolio
  48. 8.8.5 RXi Recent Developments
  49. 8.9 Quark
  50. 8.9.1 Quark Company Information
  51. 8.9.2 Quark Business Overview
  52. 8.9.3 Quark RNA-based Biopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Quark RNA-based Biopharmaceuticals Product Portfolio
  54. 8.9.5 Quark Recent Developments
  55. 8.10 Gradalis
  56. 8.10.1 Gradalis Company Information
  57. 8.10.2 Gradalis Business Overview
  58. 8.10.3 Gradalis RNA-based Biopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Gradalis RNA-based Biopharmaceuticals Product Portfolio
  60. 8.10.5 Gradalis Recent Developments
  61. 8.11 Dicerna
  62. 8.11.1 Dicerna Company Information
  63. 8.11.2 Dicerna Business Overview
  64. 8.11.3 Dicerna RNA-based Biopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Dicerna RNA-based Biopharmaceuticals Product Portfolio
  66. 8.11.5 Dicerna Recent Developments
  67. 8.12 Calimmune Inc
  68. 8.12.1 Calimmune Inc Company Information
  69. 8.12.2 Calimmune Inc Business Overview
  70. 8.12.3 Calimmune Inc RNA-based Biopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Calimmune Inc RNA-based Biopharmaceuticals Product Portfolio
  72. 8.12.5 Calimmune Inc Recent Developments
  73. 8.13 Benitec Biopharma
  74. 8.13.1 Benitec Biopharma Company Information
  75. 8.13.2 Benitec Biopharma Business Overview
  76. 8.13.3 Benitec Biopharma RNA-based Biopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Benitec Biopharma RNA-based Biopharmaceuticals Product Portfolio
  78. 8.13.5 Benitec Biopharma Recent Developments
  79. 8.14 Arrowhead Pharmaceuticals
  80. 8.14.1 Arrowhead Pharmaceuticals Company Information
  81. 8.14.2 Arrowhead Pharmaceuticals Business Overview
  82. 8.14.3 Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Arrowhead Pharmaceuticals RNA-based Biopharmaceuticals Product Portfolio
  84. 8.14.5 Arrowhead Pharmaceuticals Recent Developments
  85. 8.15 Alnylam Pharmaceuticals
  86. 8.15.1 Alnylam Pharmaceuticals Company Information
  87. 8.15.2 Alnylam Pharmaceuticals Business Overview
  88. 8.15.3 Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Alnylam Pharmaceuticals RNA-based Biopharmaceuticals Product Portfolio
  90. 8.15.5 Alnylam Pharmaceuticals Recent Developments
  91. 8.16 Abbott Laboratories
  92. 8.16.1 Abbott Laboratories Company Information
  93. 8.16.2 Abbott Laboratories Business Overview
  94. 8.16.3 Abbott Laboratories RNA-based Biopharmaceuticals Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Abbott Laboratories RNA-based Biopharmaceuticals Product Portfolio
  96. 8.16.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 RNA-based Biopharmaceuticals Value Chain Analysis
  2. 9.1.1 RNA-based Biopharmaceuticals Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 RNA-based Biopharmaceuticals Sales Mode & Process
  6. 9.2 RNA-based Biopharmaceuticals Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 RNA-based Biopharmaceuticals Distributors
  9. 9.2.3 RNA-based Biopharmaceuticals Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst